Memory clinic patients in 2026 can compare Alzheimer's blood tests by age range, accuracy, and follow-up needs. Patient Care Online reports PrecivityAD2, a blood test that estimates brain amyloid likelihood, cleared for symptomatic adults age 40 and older clearance report.
Younger-onset Alzheimer's means diagnosis before age 65, often in the 40s and 50s. Social Security Administration guidance places it at about 5-10% of all Alzheimer's cases. Age cutoffs therefore decide whether a younger adult can use a given blood test.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does PrecivityAD2 measure?
- How accurate are results?
- How do approved blood tests compare?
- What should you ask at the memory clinic?
What does PrecivityAD2 measure?
PrecivityAD2 uses high-resolution mass spectrometry to measure plasma Aβ42/40 ratio and %p-tau217. Aβ42/40 reflects amyloid protein balance in blood. Percent p-tau217 reflects tau phosphorylation linked to Alzheimer's pathology.
The two results combine into an Amyloid Probability Score 2 from 0 to 100. A higher score means brain amyloid is more likely. The score aids evaluation; it is not a stand-alone diagnosis.
How accurate are results?
NeurologyLive reports testing in 1,142 symptomatic adults against amyloid PET or spinal-fluid testing accuracy report. Positive results had 97.6% positive predictive value. Negative results had 93.1% negative predictive value. About 17.3% of results fell in an intermediate "likely positive" band.
That band had only 77.3% positive predictive value. Those patients often need clinical judgment or confirmatory PET or spinal-fluid testing. An Alzheimer's Association 2025 guideline sets separate bars for triage and substitution. Triage use needs at least 90% sensitivity plus 75% specificity. Full PET or spinal-fluid substitution needs at least 90% for both, in objectively impaired specialty-care patients.
How do approved blood tests compare?
Being Patient lists four FDA-cleared blood tests by August 2026 test comparison. They include Lumipulse, Elecsys pTau181, PrecivityAD2, and Elecsys pTau217. Earlier options were limited to ages 55 and older. For patients ages 40 to 54 with symptoms, the age cutoff matters most.
PrecivityAD2 reaches that younger group. Other cleared tests may still fit older adults in the same clinic. Accuracy reporting also differs across tests. Compare predictive values, intermediate-result rates, and whether results replace or only triage PET testing. Ask how each test performs in people with your symptom pattern.
What should you ask at the memory clinic?
PrecivityAD2 is cleared only alongside standard assessment by experienced clinicians. Memory clinics still pair it with history, cognitive testing, and sometimes PET or spinal-fluid testing. It is not for population screening. Bring details that shape interpretation.
Other medical causes, medicines, symptom timing, and family history all matter. A clear timeline helps the clinician judge borderline scores. If your score falls in the intermediate band, ask about repeat testing and referral timing. Bring a symptom timeline plus a family member who observes daily function.
- Am I in the cleared age and symptom group for this test?
- What will a positive, negative, or intermediate score change next?
- Will we still need PET or spinal-fluid testing for treatment decisions?
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Memory Clinic Patients Can Compare Testing Options
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Memory Clinic Patients Can Compare Testing Options
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
